Berkeley Lights Stock
Cell manipulation for personalized therapies
About Berkeley Lights Stock
Berkeley Lights, Inc. (BLI) is a platform for single cell manipulation that allows for researchers to analyze cells. It aims to provide platforms that automate the manipulation and analysis of cells.
The Beacon platform, the company's flagship product, is suited for cell line development, antibody discovery, gene editing, and antibody engineering workflows. The platform uses optofluidics and light-based technology to automate the work of cloning, culturing and sorting specific cells from biological samples. By automating these processes, they aim to cut the time and human labor needed to develop cell lines, discover and engineer antibodies, and do gene editing.
The company was founded in 2011 in Emeryville, California.
Investors
Funding History
| August 2011 | $183K |
|---|---|
| April 2012 | $500K |
| August 2012 | $4.0M |
| July 2014 | $29.2M |
| April 2015 | $58.6M |
| November 2016 | $40.0M |
| June 2018 | $95.0M |
Management
Chief Executive Officer
Eric Hobbs
Chief Financial Officer
Shaun Holt
Chief Scientific Officer
Kevin Chapman
Chief Technology Officer
Keith Breinlinger
Vice President, People Operations
Shari Kelleher
SVP, Antibody Therapeutics
John Proctor
SVP, Research and Development
Andrew McFarland
General Counsel
Stuart Merkadeau
Press
fiercebiotech - Oct, 1 2019
synbiobeta - Sep, 16 2019
finance - Sep, 5 2019
prnewswire - Aug, 7 2019
prnewswire - Jun, 10 2019
bioportfolio - May, 18 2019
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Berkeley Lights or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
